Skip to main content

Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.

Publication ,  Journal Article
O'Meara, E; Clayton, T; McEntegart, MB; McMurray, JJV; Piña, IL; Granger, CB; Ostergren, J; Michelson, EL; Solomon, SD; Pocock, S; Yusuf, S ...
Published in: Circulation
June 19, 2007

BACKGROUND: We wished to test previous hypotheses that sex-related differences in mortality and morbidity may be due to differences in the cause of heart failure or in left ventricular ejection fraction (LVEF) by comparing fatal and nonfatal outcomes in women and men with heart failure and a broad spectrum of left ventricular ejection fraction. METHODS AND RESULTS: We compared outcomes in 2400 women and 5199 men randomized in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program using multivariable regression analyses. A total of 1188 women (50%) had a low LVEF (< or = 0.40), and 1212 had a preserved LVEF (> 0.40). Among the men, 3388 (65%) had a low LVEF, and 1811 had a preserved LVEF. A total of 1216 women (51%) and 3465 men (67%) had an ischemic cause of their heart failure. All-cause mortality was 21.5% in women and 25.3% in men (adjusted hazard ratio [HR], 0.77; 95% CI, 0.69 to 0.86; P<0.001). Fewer women (30.4%) than men (33.3%) experienced cardiovascular death or heart failure hospitalization (adjusted HR, 0.83; 95% CI, 0.76 to 0.91; P<0.001). The risks of sudden death (HR, 0.70; 95% CI, 0.58 to 0.85) and death due to worsening heart failure (HR, 0.72; 95% CI, 0.58 to 0.89) were reduced to a comparable extent. The adjusted risk of cardiovascular hospitalization was also lower in women (HR, 0.88; 95% CI, 0.82 to 0.95), mainly because of a reduced risk of heart failure hospitalization (HR, 0.87; 95% CI, 0.78 to 0.97). Women had a lower risk of death irrespective of cause of heart failure or LVEF. CONCLUSIONS: Among patients with heart failure, women have lower risks of most fatal and nonfatal outcomes that are not explained, as previously suggested, by LVEF or origin of the heart failure.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Circulation

DOI

EISSN

1524-4539

Publication Date

June 19, 2007

Volume

115

Issue

24

Start / End Page

3111 / 3120

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Tetrazoles
  • Stroke Volume
  • Sex Characteristics
  • Risk Factors
  • Prognosis
  • Morbidity
  • Middle Aged
  • Male
  • Kaplan-Meier Estimate
 

Citation

APA
Chicago
ICMJE
MLA
NLM
O’Meara, E., Clayton, T., McEntegart, M. B., McMurray, J. J. V., Piña, I. L., Granger, C. B., … CHARM Investigators, . (2007). Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation, 115(24), 3111–3120. https://doi.org/10.1161/CIRCULATIONAHA.106.673442
O’Meara, Eileen, Tim Clayton, Margaret B. McEntegart, John J. V. McMurray, Ileana L. Piña, Christopher B. Granger, Jan Ostergren, et al. “Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.Circulation 115, no. 24 (June 19, 2007): 3111–20. https://doi.org/10.1161/CIRCULATIONAHA.106.673442.
O’Meara E, Clayton T, McEntegart MB, McMurray JJV, Piña IL, Granger CB, Ostergren J, Michelson EL, Solomon SD, Pocock S, Yusuf S, Swedberg K, Pfeffer MA, CHARM Investigators. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2007 Jun 19;115(24):3111–3120.

Published In

Circulation

DOI

EISSN

1524-4539

Publication Date

June 19, 2007

Volume

115

Issue

24

Start / End Page

3111 / 3120

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Tetrazoles
  • Stroke Volume
  • Sex Characteristics
  • Risk Factors
  • Prognosis
  • Morbidity
  • Middle Aged
  • Male
  • Kaplan-Meier Estimate